Gapping down
In reaction to disappointing earnings/guidance: CIEN -11%, FSLR -8.8%, CMTL -4.3%, MEI -4.3%, .
M&A news: FTI -1.4% ((following report that company may merge with Technip (TKPPY), later refuted by Technip)
Other news: AIXG -29.6% (announcing order reduction and impact on revenue and earnings), AXDX -10.2% (prices 5,588,236 shares of common stock at $17.00 per share), ITCI -3.6% (announces additional data from the first Phase 3 clinical trial of ITI-007; met the primary endpoint demonstrating statistically significant superiority over placebo at Day 28 as measured by the Positive and Negative Syndrome Scale), PBR -3.4% (confirms that Moody's Investors Service shifted Petrobras' rating from Ba2 to Ba3, with a negative outlook), WES -3.3% (extended its commodity price swap agreements with Anadarko (APC) for the DJ Basin complex and Hugoton system from January 1 through December 31, 2016), CSTM -3.2% (subsidiary Wise Alloys reported that it will explore alternatives to refinance its existing Asset Based Lending facility), SPWR -3.2% (in symp with FSLR), ANIK -2.9% (announces that the FDA's Office of Combination Products has assigned CINGAL to the Center for Drug Evaluation and Research as the lead center for premarket review), PE -2.7% (upsizes and prices offering of 12.35 mln shares of common stock by co and stockholders at $18.00 per share), CSIQ -2.5% (in symp with FSLR)
Analyst comments: BTI -1% (downgraded to Sell at Goldman), SNY -0.5% (downgraded to Underperform at Exane BNP Paribas
)
In reaction to disappointing earnings/guidance: CIEN -11%, FSLR -8.8%, CMTL -4.3%, MEI -4.3%, .
M&A news: FTI -1.4% ((following report that company may merge with Technip (TKPPY), later refuted by Technip)
Other news: AIXG -29.6% (announcing order reduction and impact on revenue and earnings), AXDX -10.2% (prices 5,588,236 shares of common stock at $17.00 per share), ITCI -3.6% (announces additional data from the first Phase 3 clinical trial of ITI-007; met the primary endpoint demonstrating statistically significant superiority over placebo at Day 28 as measured by the Positive and Negative Syndrome Scale), PBR -3.4% (confirms that Moody's Investors Service shifted Petrobras' rating from Ba2 to Ba3, with a negative outlook), WES -3.3% (extended its commodity price swap agreements with Anadarko (APC) for the DJ Basin complex and Hugoton system from January 1 through December 31, 2016), CSTM -3.2% (subsidiary Wise Alloys reported that it will explore alternatives to refinance its existing Asset Based Lending facility), SPWR -3.2% (in symp with FSLR), ANIK -2.9% (announces that the FDA's Office of Combination Products has assigned CINGAL to the Center for Drug Evaluation and Research as the lead center for premarket review), PE -2.7% (upsizes and prices offering of 12.35 mln shares of common stock by co and stockholders at $18.00 per share), CSIQ -2.5% (in symp with FSLR)
Analyst comments: BTI -1% (downgraded to Sell at Goldman), SNY -0.5% (downgraded to Underperform at Exane BNP Paribas
)